Explore the Agenda
8:00 am Morning Coffee, Breakfast & Check-in
8:55 am Chair’s Opening Remarks
Building Fit-for-Purpose Data to Generate Trusted RWE Across Global Markets
9:00 am Unlocking Fragmented Real-World Data Through Federated Networks & Cross-Source Collaboration
- Explore how federated data networks can help connect fragmented real-world data sources and enable research across different countries and healthcare systems
- Discuss the practical considerations involved in working across multiple data sources, including differences in data availability, structure, quality and access
- Examine how evolving research needs are creating demand for more connected and granular real-world data, and what this means for the future of RWE generation
9:30 am Building Decision-Grade RWD Through Multi-Stakeholder Data Partnerships
- Share early learnings from developing a syndicated registry model, including how greater collaboration and transparency could strengthen confidence in RWE and support its acceptance for regulatory and HTA decision-making
- Examine how sharing data infrastructure, costs and research efforts across pharmaceutical companies and healthcare organisations can reduce the time, complexity and cost of generating high-quality RWE
- Discuss the practical challenges of establishing these collaborative models, including aligning multiple stakeholders, determining fair market value for data and creating sustainable partnership frameworks
10:00 am Roundtable: Breaking down Europe’s Fragmented Data Landscape
- Debate whether greater European data connectivity will genuinely enable cross-country RWE or simply shift the challenge towards agreeing which data and populations are sufficiently comparable
- Explore how increasing access to cross-country data could affect evidence expectations for smaller European markets and country-specific treatment patterns
- Discuss whether EHDS can help pharma move beyond fragmented national datasets while balancing data privacy, ethical requirements and scientific relevance
10:30 am Morning Break & Speed Networking
The ideal opportunity to get face-to-face with many global RWE leaders for important in-depth
conversations.
Unlocking Novel Data Sources to Generate Deeper and More Actionable RWE
11:30 am Expanding Beyond Claims & EMR Data and Harnessing PatientGenerated Health Data, Wearables & Continuous Monitoring to Build a More Complete Picture of Women’s Health
- Explore how consumer health platforms, patient surveys and wearables can capture women’s experiences and outcomes that traditional healthcare datasets miss
- Demonstrate how granular, longitudinal data from devices and wearables can provide deeper insights into symptoms, sleep and day-to-day health experiences
- Examine how combining EHR and claims data with patient-generated and technology-enabled data can create a more complete, contemporary picture of the patient experience
12:00 pm Lessons From Local Evidence Generation to Strengthen Fit-for-Purpose RWE
- Drives the strategic design and oversight of non-interventional RWE initiatives using primary data collection, secondary healthcare data sources and hybrid approaches to generate fit-for-purpose evidence aligned with medical, access and policy needs across therapeutic areas
- Translates local RWE into actionable insights that address medical and access evidence gaps, support reimbursement discussions and inform managed entry agreements
12:30 pm Lunch Break & Networking
1:30 pm Combining Real-World Data + AI to Advance Preclinical Research & Early Drug Development
- Explore how real-world data and human health insights can be brought into preclinical research to complement traditional animal and laboratory data
- Examine how integrating real-world, clinical, molecular and other data modalities can support disease understanding, patient segmentation, phenotyping and identification of potential target populations
- Share practical examples of how AI, machine learning and emerging agentic approaches are being applied to accelerate research workflows, generate hypotheses and support earlier decision-making across the drug development pipeline
Harnessing AI to Accelerate Evidence Generation Without Compromising Scientific Rigor
2:00 pm If Your Evidence Is Not In The LLM, It Doesn’t Exist – Adapting RWE Strategies for the Generative AI Era
- Explore how the rise of generative AI and large language models is changing how RWE and scientific evidence is discovered, interpreted and accessed
- Share practical learnings from adapting evidence strategies to ensure RWE is effectively represented, discoverable and accurately communicated across emerging
- AI-driven information environmentsShowcase real-world examples and early results from applying these approaches across different brands and markets
2:30 pm Network & Learn Break: RWE Practical Insights Session
Continue the conversation beyond the presentations as attendees share practical examples, implementation experiences and lessons learned from across the Real World Evidence space. This session provides a unique opportunity to ask questions, exchange ideas and discover practical approaches that may not make it into formal presentations.
3:30 pm Governing AI for RWE Building Trust Through Validation Transparency & Oversight
- Establish practical frameworks for validating AI tools, assessing bias and defining gold-standard measures for AI-generated outputs
- Navigate the regulatory and compliance challenges of implementing AI in highly regulated pharmaceutical environments
- Develop governance structures, transparency requirements and human oversight models that enable responsible AI adoption across RWE teams
4:00 pm Using AI to Derive Oncology Treatment Patterns From Real-World Data
- Explore how AI can be used to derive lines of therapy and treatment patterns from claims data where detailed oncology EMR data is unavailable or difficult to access
- Share practical learnings from applying AI across different cancer types and patient populations, including how approaches need to adapt to variations in treatment pathways and data availability
- Examine how AI-derived insights can expand the use of real-world data for oncology research while addressing challenges around validation, data quality and methodological robustness
4:30 pm Closing DEBATE: Where Does the Human Touch Outweigh the Efficiency of AI?
- Take opposing sides on where AI can genuinely improve RWE and where human expertise remains essential
- Debate the trade-offs between speed, automation and efficiency versus scientific judgement, transparency and trust
- Share where organisations should draw the line between AI-led workflows and human oversight